Skip to main content
. 2021 Oct 8;39(46):6746–6753. doi: 10.1016/j.vaccine.2021.10.004

Table 1.

Participant characteristics. Data are shown as n (%).

Data (n = 282)
Age, years as M (SD) 28.9 (9.7)
Age group, years
 18–21 50(25.3)
 22–25 44(22.2)
 26–29 29(14.7)
 30–34 25(12.6)
 35–39 18(9.1)
 40–44 14(7.1)
 45–49 5(2.5)
 50–59 11(5.6)
 60–99 2(1.0)
Gender
 Female 20(7.1)
 Male 255(90.4)
 Non-binary 7(2.5)
Country
 United States 89(31.6)
 United Kingdom 22(7.8)
 Germany 21(7.4)
 Canada 20(7.1)
 France 19(6.7)
 Spain 14(5.0)
 Poland 10(3.5)
 Netherlands 9(3.2)
 Italy 8(2.8)
 Sweden 7(2.5)
 Mexico 5(1.8)
 Denmark 4(1.4)
 Ireland 4(1.4)
 Turkey 4(1.4)
 Argentina 3(1.1)
 Brazil 3(1.1)
 Japan 3(1.1)
Educational level
 Bachelor’s 84(29.8)
 High school/GED 82(29.1)
 Associate/2-year college 50(17.7)
 Master’s 36(12.8)
 Professional degree 14(5.0)
 PhD 8(2.8)
 Primary/middle school 8(2.8)
Prior VR experience
 More than 100 times 118(41.8)
 51–100 times 67(23.8)
 21–50 times 55(19.5)
 11–20 times 28(9.9)
 4–10 times 9(3.1)
 1–3 times 5(1.8)